

Surgical assessment of papillary thyroid cancer: Review

Fahad Mahdi Alsuwat, Fahad Saleh Alsuwat, Abdullah Ali Al-Ali, Ahmad Hamza Omar

Khalid, Sultan Sameer Alhunbusi, Hamdan Ahmed Althubiani, Hisham Abdulbasit

Abdulsamad Othman, Ahmed Masad Alzaidi, Abdullah Khalid Alsuwat, Maged Awadallah

Aljoud

Abstract:

This paper gave an overview of the pathological issues related to papillary thyroid carcinoma, including an update on nuclei, the benign conditions that may mimic the cancer and the implications of several subtypes of the tumor and also focused on the surgical approach of papillary thyroid cancer. We conducted computerized search among electronic databases; EMBASE, COCHRANE and MEDLINE for literature available in the databases to November, 2017 using the following search term including variants: “thyroid cancer”, “surgery”, “Management”. Restriction to only English language with human subjects were applied. The occurrence of thyroid cancer has been increasing over the past 30 years, and it is now one the most frequent cancer in females. Papillary thyroid cancer is the most common subtype of thyroid cancer. The prognosis and treatment of thyroid cancer depend on the tumor kind and its stage at the time of diagnosis. Many thyroid cancers remain stable, microscopic, and indolent. Total thyroidectomy increases survival rates and decreases recurrence rates in patients with thyroid

cancer. In general, near-total or complete thyroidectomy is suggested for the management of thyroid cancer where the primary tumor measures ≥ 1.0 centimeters to 2.0 cm. Early medical diagnosis and proper therapy could improve prognosis and reduce fatality.

Introduction:

The thyroid is an essential endocrine gland located at the base of the throat anterior to the throat. It is made up of 2 wing-shaped lobes and an isthmus that connects them, which normally could not be palpated with the skin on physical exam. The thyroid utilizes iodine to secrete hormones that control the heart rate, high blood pressure, body temperature, and basal metabolic rate.

The incidence of thyroid cancer has tripled over the last 3 decades [1], and papillary thyroid carcinoma (PTC) is the main histological subtype that has contributed to the boost [2]. Although most PTC patients can achieve an excellent long-lasting end result, survival alone as an end result measure is not adequate. In recent years, patient-centered care has come to be the major focus of clinical diagnosis and therapies. Health-related lifestyle (HRQoL) is one of the most essential areas of patient-centered care and is concentrated on exactly how patients really feel and the jobs that they can do in everyday life. HRQoL indicates the effect of the disease or the treatment on the psychological, physical, social, and somatic domains of operating or well-being [3]. HRQoL assessment is currently an increasing number of being used in scientific jobs to monitor patients' conditions and in order to help clinical decision-making, such as monitoring patients with discomfort, tracking patients with chronic illness, and so forth [4].

Most recently, the variety of new instances of thyroid cancer is approximated to be 12.9 per 100,000 men and women yearly, and the number of connected deaths is approximated to be 0.5

per 100,000 males and females annually [5]. Still, the life time threat for thyroid cancer is about 1.1%, and the 5-year survival rate has risen to 97.8%, since nearly 70% of cases are now identified at a beginning, when the cancer is localized at the gland [5].

The rise in the occurrence of thyroid cancers could be attributable to the widespread use of imaging research studies, such as ultrasounds, calculated tomography, magnetic resonance imaging, and positron emission tomography (PET) scans, that incidentally detect thyroid nodules [6].

This paper gave an overview of the pathological issues related to papillary thyroid carcinoma, including an update on nuclei, the benign conditions that may mimic the cancer and the implications of several subtypes of the tumor and also focused on the surgical approach of papillary thyroid cancer.

IJSER

Methodology:

We conducted computerized search among electronic databases; EMBASE, COCHRANE and MEDLINE for literature available in the databases to November, 2017 using the following search term including variants: “thyroid cancer”, “surgery”, “Management”. Restriction to only English language with human subjects were applied. Reference lists from all articles were scrutinized to identify any additional studies of interest.

Discussion:

- **Pathology**

The gross look of papillary thyroid cancer is rather variable. The lesions might show up anywhere within the gland. By definition, regular papillary cancers often typical 2- 3 centimeters, although lesions could be quite huge or typically subcentimeter in dimension. The lesions are firm and typically white in color with an invasive look. Lesional calcification is a common feature. Owing to the extensive sclerosis, the lesion might grossly look like a scar, especially in small lesions, which have the tendency to be found in a subcapsular place in the gland. On top of that, cyst development may be observed. In fact, some sores may be rarely practically completely cystic making diagnosis difficult [7], [8].

Microscopically, papillary carcinomas share certain functions. The neoplastic papillae contain a main core of fibrovascular (occasionally just fibrous) tissue lined by one or periodically several layers of cells with crowded oval nuclei [7], [8].

The tumors attack lymphatics causing multifocal lesions and to local node metastases. Venous intrusion rarely occurs and metastases outside the neck are unusual (5-7% of cases). Some data is available suggesting that this searching for alone is predictive of a more hostile behavior [9].

- **Thyroid Nodules**

Thyroid nodules are typical in the general populace, and a great majority of them are benign [10]. A thyroid nodule is a development of cells (a lump) in the thyroid gland, which is located in

the anterior neck region. Radiologically, they are sores within the thyroid gland that stand out from the surrounding thyroid parenchyma. It is estimated that 3% to 7% of the globe's populace have an apparent nodule, and the prevalence could raise to greater than 70% if patients are screened by ultrasound [12]. Regardless of palpability, about 5% of discovered thyroid nodules are malignant, with the exception of nodules found by PET scans, which have a 33% increased risk for malignancy [13]. Hence, newly discovered thyroid nodules are medically vital, because of the should omit thyroid cancer.

Normally, just nodules determining > 1 cm are assessed, unless there are various other threat elements that boost the suspicion for hatred. Relevant threat elements consist of a history of radiation to the head and neck region, a family history of thyroid cancer or thyroid disease, dubious ultrasound findings, lymphadenopathy, a background of goiter, female sex, and Asian origins [11].

Thyroid cancer happens more frequently in females compared to in men, at an approximate ratio of 3:1, and is a lot more common in the white and Asian/Pacific Islander populaces compared to in other populations. Thyroid cancer can occur in any kind of age-group however in grownups aged 45 to 54 years, with a mean age of 50 years at diagnosis.

Along with a thyroid blemish, the signs of thyroid cancer consist of a painless swelling in the front of the neck, trouble swallowing, trouble breathing, hoarseness, or a change in voice, among others.

- **Thyroid Cancer and Staging**

Thyroid cancer is identified histologically by means of FNA biopsy and is classified right into 4 primary types. Representing around 70% to 80% of thyroid cancers, papillary thyroid cancer is the most common thyroid malignancy [11]. Papillary thyroid carcinoma is the least aggressive kind of cancer, due to the fact that it has the tendency to expand and metastasize slowly [11]. It is composed of multifocal papillary and follicular components developing sites of adenocarcinomas.

Follicular thyroid cancer represent about 14% of thyroid cancers, is extra aggressive than papillary thyroid carcinoma, and might be connected with iodine shortage [11]. Hürthle-cell carcinoma is a variation of follicular cancer that is treated similarly as follicular carcinoma.

Medullary thyroid cancer, a cancer of nonthyroid cells that are usually existing in the thyroid gland, represents roughly 3% of thyroid cancers and is typically connected with multiple endocrine neoplasia 2. Medullary cancer creates excess calcitonin, which makes it a valuable tumor marker [11].

Anaplastic thyroid cancer stands for around 2% of thyroid cancers cells and is one of the most harmful kind of thyroid cancer, due to the fact that it metastasizes early to the surrounding lymph nodes and remote sites. Various other thyroid malignancies, such as lymphoma and variations of the 4 types mentioned above, comprise the remaining thyroid cancers. Scientifically, thyroid cancer has been separated right into 2 classifications: (1) well-differentiated, including papillary and follicular cancers, and (2) poorly separated, including medullary and anaplastic cancers.

After a medical diagnosis of thyroid cancer, it is important to carry out preoperative hosting and imaging, since it can change the patient's diagnosis and treatment program. As much as 50% of patients with set apart thyroid cancer will certainly have cervical lymph node participation,

despite the primary tumor size [11].Therefore, a preoperative neck ultrasound for contralateral lobe and cervical lymph nodes is suggested for all patients undertaking thyroidectomy for hatred, in order to help identify possible transition; however, neck ultrasounds just recognize 50% of the lymph nodes that are found throughout surgical treatment [11].

Lymph node transition can be validated by ultrasound-guided FNA on unusual lymph nodes and/or the measurement of thyroglobulin in the needle washout if it would certainly alter the disease management [11].These outcomes are then made use of to organize the level of the cancer.

The American Joint Committee on Cancer (AJCC) has marked thyroid cancer staging by the Tumor, Node, Metastasis (TNM) classification system. The AJCC's TNM category system is readily available online (at the AJCC web site).

Furthermore, thyroid cancer can be stages, utilizing stages I to IV, with the TNM classification system based on the tumor sort of thyroid cancer.

Table 1.TNM Stages of Thyroid Cancer by Tumor Type

Papillary and follicular cancer in patients aged <45 years
Stage I: papillary carcinoma is localized to the thyroid gland Stage II: papillary carcinoma that has spread distantly
Papillary and follicular cancer in patients aged ≥45 years
Stage I: papillary carcinoma is localized to the thyroid gland Stage II: tumor that is >2 cm but ≤4 cm and is limited to the thyroid gland Stage III: tumor that is >4 cm and is limited to the thyroid or with minimal extrathyroid extension or positive lymph nodes limited to the pretracheal, paratracheal, or prelaryngeal/Delphian nodes Stage IV: extension beyond the thyroid capsule to the soft tissues of the neck, cervical lymph node metastases, or distant metastases; the lungs and bone are the most frequent sites of spread
Medullary thyroid cancer
Stage 0: clinically occult disease detected by provocative biochemical screening

Stage I:	tumor	<2	cm
Stage II:	tumor >2 cm but ≤4 cm with no metastases or >4 cm with minimal extrathyroid extension		
Stage III:	tumor of any size with metastases limited to the pretracheal, paratracheal, or prelaryngeal/Delphian lymph nodes		
Stage IVA:	moderately advanced with or without lymph node metastases [for T4a], but without distant metastases		
Stage IVB:	very advanced with or without lymph node metastases, but no distant metastases		
Stage IVC:	distant metastases		
Anaplastic thyroid cancer			
All patients are considered to have stage IV disease			

- **Surgery**

Surgical choices for primary tumors consist of hemithyroidectomy, with or without isthmusectomy; near-total thyroidectomy (leaving <1 g of thyroid tissue beside the recurrent laryngeal nerve); and complete thyroidectomy (removing all noticeable thyroid tissue). In general, near-total or complete thyroidectomy is suggested for the management of thyroid cancer where the primary tumor measures ≥ 1.0 centimeters to 2.0 cm. Subtotal lobectomy and unilateral lobectomy used to be performed in the past, yet they are currently considered improper for the therapy of patients with thyroid cancer; rather, extracapsular dissection is currently recommended [14].

As a result of the high percent (42.7%) of the multifocal circulation of thyroid cancer, getting rid of the thyroid gland in its totality decreases the possibility for hatred in the residual parenchyma [15]. It likewise enables the correct danger analysis of the tumor, which is based on dimension and extracapsular infiltration [15].

Thyroidectomy is also recommended due to the fact that 5% to 10% of thyroid cancer reoccurrences are found in the contralateral lobe. The new technologic improvements in tools utilized for complete thyroidectomy, such as the hemostatic vessel-sealing tool and nerve

monitoring, have increased the safety of the procedure and the efficiency of removing the tissues in patients with malignancy [16]. Studies also reveal the cost-effectiveness of a preliminary complete thyroidectomy for nodules that are questionable for cancer based on a FNA biopsy versus preliminary lobectomy and intraoperative frozen section treatment [17].

Since lymph node metastasis can be present in 20% to 90% of patients with papillary cancer, a therapeutic central compartment neck dissection must be carried out in addition to the total thyroidectomy when lymph nodes are medically involved. Prophylactic main compartment neck dissection is additionally suggested for T3 or T4 tumors, in spite of no medically included lymph nodes. No prophylactic breakdown is advised for smaller T1 or T2 noninvasive tumors.

Today, thyroidectomy is mainly done as an outpatient surgical procedure [18]. With proper education and therapy, patients are more apt to select outpatient surgery; nevertheless, for the safety of the patient, contraindications have to be taken into consideration. The contraindications for outpatient thyroidectomy include noncompensated cardiac and/or respiratory system disease, dialysis-dependent renal failing, anticoagulant treatment, seizure problem, obstructive rest apnea, mental disability, maternity, independent singing layer paralysis, thyrotoxicosis, and morbid obesity [19]. Various other factors, such as assistance from friend or family and psychological stability, are essential to the result of the outpatient surgery.

An evaluation of 5121 patients undergoing outpatient thyroidectomy suggested that the morbidity and readmission rates are very low, with 0.92% of patients having perioperative morbidities and 2.17% of patients being readmitted within 30 days of the operation [18]. However, as with any treatment, problems could occur. The 2 most common early postoperative complications of

thyroidectomy are hypocalcemia (20%- 30%) and reoccurring laryngeal nerve injury (5%- 11%) [20].

The threat for postoperative hypocalcemia is increased by a number of aspects, consisting of the venous drainage of the top parathyroid glands, the area of the parathyroid glands and difficulty in recognizing them, the visibility of huge goiters, Graves' disease, thyroid cancer that requires a considerable dissection of lymph nodes, and repeat expedition of the cervical region resulting in adhesions, along with young age and women sex [20]. The danger for injury to the persistent laryngeal nerve is low, with an uncommon complication of reciprocal reoccurring laryngeal nerve palsy. The danger for injury to the nerve is raised by reoperation, the underlying thyroid pathology, the intrusion of surrounding structures, and the degree of the resection [20]. An additional issue is postoperative hemorrhage, the incidence which rises with increases in the weight and size of the thyroid gland [20].

Unilateral lobectomy involves a smaller personnel area than total thyroidectomy. Hematomas take place in about 1% of patients, with occasions occurring within the initial 6 hours after surgery [20]. The very early signs of hematoma consist of noticable anterior swelling, feeling of tightness, and purple discoloration of the skin. The late indicators of hematoma may consist of breathing stridor and distress. With very early care and patient education about the signs of hematomas, same-day health center discharge has been revealed to be safe [19].

Conclusion:

The occurrence of thyroid cancer has been increasing over the past 30 years, and it is now one the most frequent cancer in females. Papillary thyroid cancer is the most common subtype of thyroid cancer. The prognosis and treatment of thyroid cancer depend on the tumor kind and

its stage at the time of diagnosis. Many thyroid cancers remain stable, microscopic, and indolent. Total thyroidectomy increases survival rates and decreases recurrence rates in patients with thyroid cancer. In general, near-total or complete thyroidectomy is suggested for the management of thyroid cancer where the primary tumor measures ≥ 1.0 centimeters to 2.0 cm. Early medical diagnosis and proper therapy could improve prognosis and reduce fatality.

Reference:

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. *CA Cancer J Clin* 2016;66:7–30.
2. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. *CA Cancer J Clin* 2016;66:115–32.
3. Revicki DA, Osoba D, Fairclough D, et al. Recommendations on health-related quality of life research to support labeling and promotional claims in the United States. *Qual Life Res* 2000;9:887–900.
4. Franklin PD, Allison JJ, Ayers DC. Beyond joint implant registries: a patient-centered research consortium for comparative effectiveness in total joint replacement. *JAMA* 2012;308:1217
5. National Cancer Institute. SEER stat fact sheets: thyroid cancer. <http://seer.cancer.gov/statfacts/html/thyro.html>. Accessed January 12, 2015.
6. Knox MA. Thyroid nodules. *Am Fam Physician*. 2013; 88: 193–196.
7. Rosai J, Carcangui ML, DeLellis RA. Tumors of the Thyroid Gland. *Atlas of Tumor Pathology, Fascicle 5*. Armed Forces Institute of Pathology: Washington, DC, 1992.
8. Baloch Z, LiVolsi VA. Pathology of the thyroid gland. In: Livolsi VA, Asa S (eds). *Endocrine Pathology*. Churchill Livingstone: Philadelphia, PA, 2002, pp 61–88.

9. Gardner RE, Tuttle RM, Burman KD. Prognostic importance of vascular invasion in papillary thyroid carcinoma. *Arch Otolaryngol Head Neck Surg* 2000;**126**:309–312.
10. Knox MA. Thyroid nodules. *Am Fam Physician*. 2013; **88**: 193–196.
11. Cooper DS, Doherty GM, Haugen BR, et al. for the American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer. Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer: the American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer. *Thyroid*. 2009; **19**: 1167–1214. Errata in: *Thyroid*. 2010;**20**:674–675; *Thyroid*. 2010;**20**:942.
12. Corso C, Gomez X, Sanabria A, et al. Total thyroidectomy versus hemithyroidectomy for patients with follicular neoplasm. A cost-utility analysis. *Int J Surg*. 2014; **12**: 837–842.
13. Welker MJ, Orlov D. Thyroid nodules. *Am Fam Physician*. 2003; **67**: 559–566.
14. Nixon IJ, Ganly I, Shah JP. Thyroid cancer: surgery for the primary tumor. *Oral Oncol*. 2013; **49**: 654–658.
15. 14. Lucchini R, Monacelli M, Santoprete S, et al. Differentiated thyroid tumors: surgical indications. *G Chir*. 2013; **34**: 153–157.
16. Rudolph N, Dominguez C, Beaulieu A, et al. The morbidity of reoperative surgery for recurrent benign nodular goitre: impact of previous unilateral thyroid lobectomy versus subtotal thyroidectomy. *J Thyroid Res*. 2014; **2014**: 231857.
17. Leiker AJ, Yen TW, Cheung K, et al. Cost analysis of thyroid lobectomy and intraoperative frozen section versus total thyroidectomy in patients with a cytologic diagnosis of “suspicious for papillary thyroid cancer.” *Surgery*. 2013; **154**: 1307–1313; discussion 1313–1314.
18. Khavanin N, Mlodinow A, Kim JYS, et al. Predictors of 30-day readmission after outpatient thyroidectomy: an analysis of the 2011 NSQIP data set. *Am J Otolaryngol*. 2014; **35**: 332–339.

19. Terris DJ, Snyder S, Carneiro-Pla D, et al. for the American Thyroid Association Surgical Affairs Committee Writing Task Force. American Thyroid Association statement on outpatient thyroidectomy. *Thyroid*. 2013; 23: 1193–1202.
20. Christou N, Mathonnet M. Complications after total thyroidectomy. *J Visc Surg*. 2013; 150: 249–256.

IJSER